Halozyme Therapeutics/$HALO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Halozyme Therapeutics
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Ticker
$HALO
Sector
Primary listing
Employees
423
Headquarters
Website
HALO Metrics
BasicAdvanced
$8.1bn
24.13
$2.84
0.88
-
Price and volume
Market cap
$8.1bn
Beta
0.88
52-week high
$82.22
52-week low
$51.06
Average daily volume
2m
Financial strength
Current ratio
2.762
Quick ratio
2.138
Long term debt to equity
896.17
Total debt to equity
976.451
Interest coverage (TTM)
44.97%
Profitability
EBITDA (TTM)
953.01
Gross margin (TTM)
76.67%
Net profit margin (TTM)
23.13%
Operating margin (TTM)
56.96%
Effective tax rate (TTM)
30.70%
Revenue per employee (TTM)
$3,570,000
Management effectiveness
Return on assets (TTM)
22.06%
Return on equity (TTM)
99.40%
Valuation
Price to earnings (TTM)
24.13
Price to revenue (TTM)
5.388
Price to book
36.99
Price to tangible book (TTM)
-6.18
Price to free cash flow (TTM)
21.396
Free cash flow yield (TTM)
4.67%
Free cash flow per share (TTM)
3.204
Growth
Revenue change (TTM)
39.12%
Earnings per share change (TTM)
-24.42%
3-year revenue growth (CAGR)
28.86%
10-year revenue growth (CAGR)
25.24%
3-year earnings per share growth (CAGR)
29.76%
10-year earnings per share growth (CAGR)
25.62%
What the Analysts think about HALO
Analyst ratings (Buy, Hold, Sell) for Halozyme Therapeutics stock.
HALO Financial Performance
Revenues and expenses
HALO Earnings Performance
Company profitability
HALO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs